Earnings Report: Here’s what to expect from NYSE:RVI, NYSE:RC, NASDAQ:SYBX, NYSE:AIM

0
77

RETAIL VALUE EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NYSE:RVI)

IS RETAIL VALUE A BUY RIGHT NOW? (NYSE:RVI)

2 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Retail Value in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Retail Value stock.
Retail Value

READY CAPITAL (NYSE:RC) EARNINGS INFORMATION (NYSE:RC)

Ready Capital last issued its earnings data on March 10th, 2021. The real estate investment trust reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.10. Ready Capital has generated $1.54 earnings per share over the last year and currently has a price-to-earnings ratio of 21.3. Ready Capital has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, May 10th, 2021 based off prior year’s report dates.

IS READY CAPITAL A BUY RIGHT NOW? (NYSE:RC)

6 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Ready Capital in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Ready Capital stock.
Ready Capital

SYNLOGIC EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:SYBX)

IS SYNLOGIC A BUY RIGHT NOW? (NASDAQ:SYBX)

3 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Synlogic in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Synlogic stock.
Synlogic

AIM IMMUNOTECH EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NYSE:AIM)

IS AIM IMMUNOTECH A BUY RIGHT NOW? (NYSE:AIM)

2 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for AIM ImmunoTech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” AIM ImmunoTech stock.
AIM ImmunoTech